Tert-Butyl N-(2-Hydroxypropyl)Carbamate 98.0%

Ranolazine(RS-43285) is an antianginal agent with antiarrhythmic properties that achieves its effects via a novel mechanism of action (inhibition of the late phase of the inward sodium current) without affecting heart rate or blood pressure (BP). IC50 valueTarget sodium-dependent calcium channelRanolazine is currently approved for use in chronic angina. The basis for this use is likely related to inhibition of late sodium channels with resultant beneficial downstream effects. Randomized clinical trials have demonstrated an improvement in exercise capacity and reduction in angina episodes with ranolazine.

For R&D use onlynot for drug household or other uses.

Ranolazine Dihydrochloride is an anti-ischemic agent which modulates myocardial metabolism. Antianginal.